High Purity Pharmaceutical Pirfenidone Raw Material Anti Fibrosis Piresupa Factory Supply

High Purity Pharmaceutical Pirfenidone Raw Material Anti Fibrosis Piresupa Factory Supply

Pirfenidone Specification:

Application

In vitro, pirfenidone can inhibit the uterine flesh tumour cells and leiomyoma cells proliferation. Pirfenidone can inhibit the TGF – beta – 1 inducing fibroblast collagen formation. Inhibition of PDGF, FGF and TGF – beta – 1 inducing fibroblast proliferation. In hamster model, pirfenidone, taken by mouth, that can the prevention and treatment of pulmonary fibrosis induced by bleomycin. Pirfenidone can prevent the sclerosing peritonitis in rats induced by chemical, can also be keloid grafting for the treatment of nude mice. Pirfenidone 0.01 1 mg/ml can suppress the matrix and dose dependent manner serum stimulate uterine fibroids and leiomyoma cell DNA synthesis, the compound has no cytotoxic effect, has no effect on collagen mRNA level also. Pirfenidone in hamster pulmonary fibrosis model can reduce the disease before the collagen I mRNA level enhancement, reduce the level of the lung hydroxyproline and malondialadehyde and lung preserved ammonia acyl hydroxylase activity.

Description

In the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) study, a randomized, double-blind, placebo-controlled trial, we aimed to confirm the effect of pirfenidone on disease progression in patients with idiopathic pulmonary fibrosis. Our design modifications with respect to the CAPACITY trial included the implementation of centralized procedures for diagnosis, spirometry, ,

Pirfenidone is an oral antifibrotic therapy that has been evaluated for the treatment of idiopathic pulmonary fibrosis in three phase 3, randomized, controlled trials. One of these trials was conducted in Japan and involved 275 patients. It was followed by two multinational studies, Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes, that were conducted in the United States, Europe, and Australia and involved 779 patients.7,8 In the Japanese trial, pirfenidone reduced the decline in vital capacity at week 52 and improved progression-free survival. In the multinational trials, the primary end point of change from baseline to week 72 in the percentage of the predicted forced vital capacitywas met in study 004 but not in study 006, prompting U.S. regulatory authorities to request an additional trial to support the approval of pirfenidone.